Dr. Scott Rocklage: Working On The Cutting-Edge Of Medical Breakthroughs
Scientist and entrepreneur Dr. Scott Rocklage is the managing partner at the venture capital firm 5AM Ventures. The company invests in and supports early stage life science companies and helps them to turn their innovative ideas into medicines and technologies to help patients worldwide. Dr. Rocklage has been with 5AM Ventures since 2003, first as a venture partner then as managing partner. Prior to working with the venture capital firm, Dr. Scott Rocklage at spent over 30 years working in the healthcare management and biotech industries.
A talented scientist and inventor, Dr. Rocklage has almost 3 dozen U.S. patents. He has also helped several drugs to get FDA approval and gotten many others into clinical trials. Plus, his writings have appeared in countless peer-reviewed science focused publications. In addition to his years of research experience, Dr. Scott Rocklage has a bachelor’s degree in chemistry from UC Berkley and a Ph.D. in chemistry from MIT. He also has extensive leadership experience with and is on the board of directors of numerous biotech companies.
Some of the companies with which Dr. Rocklage is or has been involved include Expansion Therapeutics, Novira Therapeutics, Inc., Rennovia Inc., Nouscom AG, Cidara Therapeutics, Inc., Cubist Pharmaceuticals LLC, Protana Inc., Amersham Health, Miikana Therapeutics Inc., Achaogen, Inc., Ilypsa, Inc. and Pulmatrix, Inc. For years Dr. Scott Rocklage has worked closely with doctors, scientists, business executives, researchers and entrepreneurs to create products and services that can cure disease, prolong life and improve the quality of life for people suffering with cancer and other debilitating diseases and conditions.
For years Dr. Rocklage has been working with scientists, researchers and medical professionals on the cutting-edge of medical breakthroughs. He is very excited about the progress being made in developing innovative new ways to treat cancer by targeting specific genotypes and mutations and how that will dramatically impact cancer care in the near future. At 5AM Ventures Dr. Rocklage works closely with the company’s portfolio management team to identify other companies in which to invest. The company is in an excellent position to help to usher in unique new medical treatments.
Throughout his career Dr. Scott Rocklage has been known for his excellent organizational and time management skills, measured risk-taking and entrepreneurship. He sees those things as being very important for meaningful medical breakthroughs. For people seeking a better understanding of business and performance, Dr. Rocklage recommends reading ‘Good to Great’.
Scott Rocklage, Ph.D. started his career at Berkley University in California with a B.S. in chemistry. He then went on MIT, Massachusetts Institute of Technology and earned his Ph.D. in the lab of 2005 Nobel Prize winner Dr. Richard Schrock. He considers it lucky and a great honor to have been able to work with Dr. Schrock. Since then he has become a leading figure in healthcare management. Read more: Idea Mensch | Scott Rocklage
He currently is a managing partner at 5AM Ventures. He came to them in 2004 as a Venture Partner in 2003 and became a managing partner in 2004. Dr. Rocklage was well prepared for this role because of his twenty years plus working in healthcare management.
Examples of his leadership capabilities allowed Dr. Rocklage and his team to have the approval of a few drug applications in the US. They include Cubicin, Teslascan, and Omniscan. He also holds over twenty US patents and has had six drug candidates enter into clinical drug trials.
Dr. Rocklage not only is a managing partner at 5Am Ventures but sits and has sat on the board of several other companies. He once served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, President, CEO and Chairman of Nycomed Interventional and has also held various R&D positions at Salutar and Catalytica.
He also was formerly the Executive Chairman of Ilypsa (acquired by Amgen) and Miikana (acquired by EntreMed). Currently, he serves as Board Chairman of Achaogen, Relypsa and Semprus as well as on the Boards of WaveRx, Pulmatrix and Variation and the Board of Associates at the Whitehead Institute. Learn more about Scott Rocklage: http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY
Not only is he a man of science and management he’s a philanthropist. When approached by his alma mater MIT about donating he responded with sure where are you in the most need? He and his wife Patty were honored last year with their major gift that assisted with the costs associated with the renovation of Lester Wolfe Professor of Chemistry, Moungi Bawendi’s nanochemistry and nanotechnology lab space in Building 2.
Read more: Scott Racklage | Bloomberg